TaiMed Biologics Profit Margin

The latest profit margin for 4147.TWO is -22.42% as of June 2026. That compares with -40.72% in the prior-year period — up 44.9% year over year. That is below the Healthcare sector average of 9.71%. Investors often review this figure alongside TaiMed Biologics's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4147.TWO's profit margin moved from -40.72% to -22.42% — a 44.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in TaiMed Biologics's valuation or profitability profile.

Against Healthcare companies, 4147.TWO currently prints -22.42% for profit margin, while the sector average sits near 9.71%. That is roughly 331.0% below the sector mean. Large gaps often invite a closer look at TaiMed Biologics's growth, margins, and balance sheet.

Profit Margin shows how effectively TaiMed Biologics converts resources into returns. At -22.42%, 4147.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -40.72% in the prior-year period — up 44.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 4147.TWO's profit margin (-22.42%), review year-over-year change from -40.72%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.